dapagliflozin/metformin hydrochloride extended-release

Dapagliflozin functions in the kidneys to inhibit glucose absorption, resulting in decreased blood sugar levels. Meanwhile, Metformin hinders sugar absorption from the stomach, reduces the release of stored sugar from the liver, and enhances the body’s utilization of sugar.

Dapagliflozin was found to decrease the likelihood of kidney failure, cardiovascular-related death, and hospitalization for heart failure in individuals with chronic kidney disease, regardless of whether they had type 2 diabetes or concomitant cardiovascular disease. Additionally, it was observed to improve overall survival rates.

Dapagliflozin is primarily prescribed for the treatment of type 2 diabetes. Additionally, it may be used to address heart failure and chronic kidney disease (CKD). Dapagliflozin is typically recommended in cases where metformin cannot be taken by individuals with type 2 diabetes.

Symptoms may include bladder discomfort, alterations in vaginal discharge color, quantity, or smell, and lower back or side discomfort.

According to the report, individuals without diabetes who were given dapagliflozin 10 mg once daily experienced a 27% reduction in the composite primary endpoint of cardiovascular death, heart failure hospitalization, and urgent heart failure visits over an average 18.2 months, compared to those who received a placebo (HR 0.73, 95% CI 0.60-0.88).

If you have kidney or liver disease, low blood pressure (hypotension), frequent urinary tract infections (UTIs), or are scheduled for surgery, please consult with your healthcare provider for appropriate management and precautions.

Chronic kidney disease (CKD) patients with proteinuria (stage 2, 3, or 4 and urine ACR 30 mg/mmol) can take 10 mg tablets of dapagliflozin to lower the risk of worsening kidney function.

Drug group or drug name
Drug examples
insulin
– insulin degludec (Tresiba)
– insulin glargine (Lantus, Basaglar)
– insulin lispro (Humalog)
– insulin regular (Humulin R)

sulfonylureas
– glipizide (Glucotrol XL)
– glyburide (Diabeta, Glynase)
– glimepiride (Amaryl)

lithium (Lithobid)

Symptoms: feeling or being sick, feeling very thirsty, feeling confused or unusually tired, having stomach pain, breath that smells fruity, breathing more deeply or faster.

Dapagliflozin functions by reducing blood sugar levels in individuals with type 2 diabetes. It achieves this by facilitating the elimination of excess sugar from the body through urine. Moreover, for individuals with heart failure, dapagliflozin lessens the workload on the heart by aiding in the efficient circulation of blood throughout the body.

The administration of Dapagliflozin resulted in a notable reduction in body weight and overall fat mass, while having no impact on skeletal muscle mass. The variance in soft lean mass and skeletal muscle mass between groups was not statistically significant.

Research on dapagliflozin has proven its effectiveness as a standalone treatment as well as when used alongside oral antihyperglycemic agents and insulin. It has been observed that dapagliflozin can reduce hemoglobin A1c (HbA1c) levels by 6 mmol/mol (0.5%) to 8 mmol/mol (0.7%).

It depends on what clinical perspective dapagliflozin may be better than metformin. For example, In a 12-week study, patients who took dapagliflozin 10 mg daily experienced a 2.7% reduction in body weight (95% confidence interval -3.5 to -1.8%), while those in the metformin group had a weight loss of 1.7% (95% CI -2.4 to -0.9%).

You have the option to take them with or without food. However, if you are taking dapagliflozin with metformin, it is recommended to take it with food or shortly after.

It is important to avoid consuming alcohol on an empty stomach or after exercising, as this can raise the risk of hypoglycemia. Be sure to inform your doctor about all medications, including vitamins and herbs, that you are taking. Do not discontinue any medications without consulting your doctor first.

It is advised to reduce alcohol consumption while using this medication as it can raise the risk of experiencing low blood sugar and high ketone levels. If you have diabetes, managing your blood sugar levels may become more challenging during times of stress, such as when experiencing fever, infection, injury, or undergoing surgery.

If you are experiencing thrush, it is advisable to consult your pharmacist for a recommended antifungal treatment. In the case of sudden and unexpected back pain, it is important not to attempt self-treatment and seek professional medical advice. Increased frequency of urination may indicate the presence of excess sugar in your urine. If you are feeling dizzy, it is recommended to consult a healthcare professional. Lastly, if you have a mild skin rash, it is advisable to seek medical advice.

Taking metformin, specifically glucophage retard, before bed instead of before supper may help manage diabetes better by reducing high blood sugar levels in the morning.

Dapagliflozin does not have any impact on contraception, including the combined pill and emergency contraception.

To ensure the proper functioning of extended-release metformin in reducing your blood sugar level, it is recommended to take your dose once daily at night, along with your last meal of the day. If you have any inquiries regarding the optimal timing for taking metformin, it is advisable to consult your doctor or pharmacist.

Farxiga (dapagliflozin) is an oral tablet prescribed for Type 2 diabetes treatment. It is also approved by the FDA for managing chronic kidney disease and heart failure. It is recommended to take Farxiga in the morning, regardless of food intake.

Before beginning treatment with Farxiga, it is crucial to consult your doctor if you have kidney issues, such as chronic kidney disease. This medication heightens the likelihood of dehydration, which can result in low blood pressure and kidney failure. To prevent these complications, it is essential to stay well-hydrated by consuming ample fluids.

Farxiga (dapagliflozin) is an oral tablet prescribed for Type 2 diabetes treatment. It is also approved by the FDA for managing chronic kidney disease and heart failure. It is recommended to take Farxiga in the morning, regardless of food intake.

It is advised to reduce alcohol consumption while using this medication as it can raise the risk of experiencing low blood sugar and high ketone levels. If you have diabetes, managing your blood sugar levels may become more challenging during times of stress, such as when experiencing fever, infection, injury, or undergoing surgery.

When taking Farxiga, it is important to be cautious of interactions with vitamins and minerals. Combining Farxiga with chromium can potentially lead to a significant drop in blood sugar levels. If you are prescribed a chromium supplement while taking Farxiga, your doctor may advise you to monitor your blood sugar levels more frequently.

Postmarketing studies have revealed that Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as Farxiga (dapagliflozin), have the potential to induce acute kidney injury (AKI). Consequently, Farxiga’s product label and Medication Guide have been updated to include warnings regarding the risk of kidney injury.

Dapagliflozin (n = 28) and non-SGLT2i (n = 22) groups were compared at baseline and after 6 months. The absolute change in BMI was -1.2 ± 0.9 kg/m2 for the dapagliflozin group and -0.4 ± 0.8 kg/m2 for the non-SGLT2i group. The body weight at baseline was 76.7 ± 7.4 kg for the dapagliflozin group and 70.6 ± 10.8 kg for the non-SGLT2i group. The absolute change in body weight was -3.4 ± 2.6 kg for the dapagliflozin group and -1.1 ± 2.0 kg for the non-SGLT2i group.

Instructions: Take dapagliflozin orally once daily, with or without food. It is important to continue following your prescribed diet and exercise routine while taking dapagliflozin. Please note that dapagliflozin may cause glucose to be present in your urine. Your healthcare provider may conduct specific blood tests before you begin dapagliflozin and periodically throughout your treatment.

Farxiga begins to take effect after a single dose, but it may require up to a week to achieve its maximum potential. For individuals with type 2 diabetes, Farxiga functions by preventing the reabsorption of glucose into the body through the kidneys, resulting in a greater amount of glucose being expelled during urination.

The effectiveness of long-term use of dapagliflozin has not been studied in terms of morbidity or mortality benefits. However, in patients who take dapagliflozin (10 mg once daily) as monotherapy, it has been observed that A1C levels decrease by an average of 0.7 percentage points more than placebo (with a 95% confidence interval of 0.4% to 1.0% lower).

Farxiga (dapagliflozin) can also reduce the likelihood of severe complications, hospitalization, and mortality in specific individuals with heart failure or chronic kidney disease (CKD). However, it may increase urination frequency and elevate the risk of dehydration.

To ensure the effectiveness of Farxiga treatment, it is advisable to restrict your alcohol intake. This is because alcohol has the potential to elevate your blood sugar levels, which can exacerbate your diabetes. Moreover, it is important to note that Farxiga can lead to the development of diabetic ketoacidosis.

This medication is available as both a brand name drug and a generic version. The average cost for a 30-day supply of 5MG tablets is $1,089.91. However, you can purchase Farxiga at a discounted price of $618.01 by using the NowPatient Rx Advantage Card, which will save you 43%. We advise you to compare prices even if this drug is covered by Medicare or your insurance.

According to clinical studies, individuals who took Farxiga alone, at either a daily dosage of 5 mg or 10 mg, experienced an average weight loss of approximately 6 pounds over a period of 24 weeks. Additionally, the studies revealed that when Farxiga was taken in combination with metformin, another medication for type 2 diabetes, the average weight loss ranged from 6 to 7 pounds over the same 24-week duration.

Xigduo XR is a medication that combines dapagliflozin and metformin. It is used to treat type 2 diabetes. The recommended starting dose is 5 mg dapagliflozin/500 mg metformin twice daily, with gradual dose adjustments based on individual response.

Xigduo XR works by increasing the removal of glucose from the body through the kidneys and reducing the production of glucose in the liver. It can be used as monotherapy or in combination with other antidiabetic medications.

There are several important drug interactions to be aware of when taking Xigduo XR. It may interact with medications that affect renal function, such as diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs). It is also important to monitor for signs of lactic acidosis when Xigduo XR is used in combination with medications that can increase the risk of this condition, such as contrast agents.

Common adverse effects of Xigduo XR include urinary tract infections, genital mycotic infections, and increased urination. It may also cause hypoglycemia when used in combination with insulin or insulin secretagogues.

Xigduo XR should be used with caution in patients with renal impairment, as it can increase the risk of lactic acidosis. It is not recommended for use in patients with severe renal impairment or end-stage renal disease.

In conclusion, Xigduo XR is a combination medication used to treat type 2 diabetes. It has specific dosing recommendations, potential drug interactions, and adverse effects that should be considered when prescribing or taking this medication.

Farxiga and Jardiance are both SGLT2 inhibitors, but they contain different active ingredients. Farxiga contains dapagliflozin, while Jardiance contains empagliflozin.

Dapagliflozin functions in the kidneys to inhibit glucose absorption, resulting in decreased blood sugar levels. Meanwhile, Metformin hinders sugar absorption from the stomach, reduces the release of stored sugar from the liver, and enhances the body’s utilization of sugar.

Forxiga (dapagliflozin) is an innovative oral medication that belongs to the SGLT2 inhibitor class. It is taken once daily and has been proven through research to effectively prevent and delay cardiorenal disease. Additionally, Forxiga has shown to provide protection to vital organs, which is significant considering the interconnectedness of the heart, kidneys, and pancreas. These findings highlight the potential benefits of Forxiga in maintaining overall organ health.

Xigduo XR (dapagliflozin / metformin) is a combination drug that, when used in conjunction with a balanced diet and regular exercise, is prescribed for the treatment of Type 2 diabetes. It not only reduces blood sugar levels but also decreases the likelihood of developing associated health complications, such as deteriorating heart failure or chronic kidney disease (CKD).

Dapagliflozin, metformin, and Ozempic (semaglutide) are available in various dosage forms including oral solution, oral tablet, extended-release oral tablet, and subcutaneous solution. These medications are also sold under the brand names Farxiga and Glumetza, while other semaglutide brands include Rybelsus and Wegovy.

AstraZeneca’s Farxiga (dapagliflozin) has received approval in the United States for the purpose of reducing the likelihood of cardiovascular death, hospitalization for heart failure, and urgent visits related to heart failure in adults with heart failure.

Farxiga contains the active ingredient dapagliflozin, which is also available in generic form. Generic drugs are deemed to be equally safe and effective as the original drug.

It is recommended to take Farxiga (dapagliflozin) in the morning, regardless of whether you have eaten or not. If you experience symptoms of a yeast or urinary tract infection while taking Farxiga, it is important to contact your healthcare provider.